UPDATE: As of November 2012, there is an additional dedicated site to inquire about participating in this study at http://www.ibsdstudy.com Thank you to Western States Clinical Research for this updated information.
This study is posted at the request of Western States Clinical Research, Inc. in Wheat Ridge, Colorado, one of many participating study sites throughout the U.S.
This Phase II study for Lexicon Pharmaceuticals investigational medication, LX-1033, (3 doses over 4 weeks or placebo) is seeking men and women ages 18-70 who have had IBS symptoms for at least 6 months, diarrhea predominant at least 75% of the time symptoms are active, and moderate abdominal pain. Potential volunteers near Western States Clinical Research may call 303-940-0909 or contact at http://www.wscrinc.com Accepted participants will receive relevant medical exams and study medication free of charge and be compensated for time and travel. Interested people in other U.S. locations, see Clinical Trials.gov Lexicon Phase II LX-1033 for other sites involved in this study.
Previous posts on open clinical trials for IBS can be found by clicking the clinical trials category in the blog archives on the upper right sidebar of this blog. We also have a page for IBS studies on the main IBS Impact site, which has just been updated as of July 2012 The research and links pages and the July 26, 2011 post provide additional general resources.
We welcome researchers affiliated with academic, medical or pharmaceutical entities, or reputable organizations representing IBS or related or commonly overlapping conditions, to contact us directly with additional studies they wish to be considered for posting. Contact links for the founder/listowner and the webmaster can be found on the home page of the main IBS Impact website.
IBS Impact makes these study announcements available for general information, and encourages its members and site visitors to make their own individual, informed choices about their potential participation in any study. IBS Impact, as an entity, is not directly affiliated with any research sponsor and receives no funding from any source for studies or links we feature on this blog, the main site or social media.